title: Development of a curative treatment within the AML-BFM studies.
abstract: The first multicenter treatment study for AML in childhood in Germany was performed from 1978 onwards. The therapy plan was designed similar to that for the acute lymphoblastic leukaemia (ALL). The drugs with the highest efficacy in AML, cytarabine cutting catara-bine and anthracyclines, were combined during induction and consolidation, followed by preventive cranial irradiation and maintenance therapy similar to that in ALL. The remission rate of the initial study was 80%, and the 5-year survival rate increased from less than 10% before 1970 to 40%. 5 subsequent trials have further increased the 5-year survival to now 70% and even 90% in the subgroup of core-binding factor leukaemias by using an intensified and optimised treatment schedule.The AML-BFM studies were the only prospective study sequence testing the benefit of cranial irradiation. Results from study -87 including the non-randomized patients showed an increased risk of CNS and/or bone marrow relapses in non-irradiated patients. Later on there was evidence that 12 Gy resulted in the same relapse rate as 18 Gy. The AML-BFM studies always used the experience from the previous study to optimize the next study. This approach was essential together with improved supportive treatment and experience of the medical staff for the step-wise and considerable increase of longterm survival within the 6 subsequent AML-BFM studies.
authors.affiliation: Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany. ursula@creutzig.de
authors.forename: U
authors.initials: U
authors.lastname: Creutzig
authors.forename: M
authors.initials: M
authors.lastname: Zimmermann
authors.forename: M N
authors.initials: MN
authors.lastname: Dworzak
authors.forename: J
authors.initials: J
authors.lastname: Ritter
authors.forename: G
authors.initials: G
authors.lastname: Schellong
authors.forename: D
authors.initials: D
authors.lastname: Reinhardt
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use; D004915:Leukemia, Erythroblastic, Acute / Q000401:mortality / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000401:mortality / Q000628:therapy; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013866:Thioguanine / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate; D015255:Idarubicin; D003630:Daunorubicin